汉森制药(002412) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥213,535,931.23, an increase of 0.50% year-over-year, while total revenue for the year-to-date was ¥693,981,713.71, up 1.44% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥30,259,047.62, a significant increase of 58.63% year-over-year, with year-to-date net profit at ¥130,753,045.98, up 19.15%[2] - Basic earnings per share for Q3 2024 was ¥0.0601, reflecting a growth of 58.58% compared to the same quarter last year[2] - Total operating revenue for Q3 2024 reached CNY 693,981,713.71, an increase from CNY 684,141,818.56 in Q3 2023, representing a growth of approximately 1.23%[15] - Net profit for Q3 2024 was CNY 130,753,045.98, compared to CNY 109,742,317.45 in Q3 2023, reflecting an increase of approximately 19.14%[16] - Earnings per share (EPS) for Q3 2024 was CNY 0.2598, up from CNY 0.2181 in Q3 2023, indicating a growth of about 19.03%[17] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥2,452,685,109.60, representing a 4.97% increase from the end of the previous year[2] - The total assets of the company reached ¥2,452,685,109.60, up from ¥2,336,488,623.93, reflecting a growth of approximately 5%[12] - The total liabilities decreased to CNY 351,412,931.28 from CNY 373,459,685.26, a decline of approximately 5.88%[14] - The total equity attributable to shareholders increased to CNY 2,101,272,178.32 from CNY 1,963,028,938.67, representing a growth of about 7.05%[14] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥138,988,518.22, an increase of 27.07% year-over-year[2] - The net cash flow from operating activities amounted to ¥138,988,518.22, an increase of 27.1% compared to ¥109,378,757.22 in the previous period[20] - Total cash inflow from operating activities was ¥800,970,314.53, up from ¥784,850,845.91, reflecting a growth of 2.8%[20] - The net cash flow from investment activities was -¥114,233,695.83, a significant decrease compared to a positive cash flow of ¥1,738,334.14 in the previous period[20] - The net cash flow from financing activities was -¥13,985,347.79, an improvement from -¥180,922,056.58 in the previous period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,904[9] - Hainan Hansen Holdings (Limited Partnership) holds 42.13% of the shares, making it the controlling shareholder[10] - The number of shares held by the top ten shareholders includes significant stakes from Hainan Hansen Holdings and Shanghai Fosun Pharmaceutical Industry Development Limited, with the top ten shareholders holding a combined total of 42.13% and 4.82% respectively[10] Expenses and Income - The company reported a decrease in financial expenses by ¥779,489.35, a decline of 39.16% year-over-year, primarily due to reduced bank loans[6] - Investment income decreased by ¥39,362,876.13, down 89.25% year-over-year, mainly due to reduced earnings from equity investments[6] - Other income increased by ¥2,808,591.18, a growth of 86.94% year-over-year, attributed to government subsidies received[6] - Research and development expenses for Q3 2024 were CNY 27,453,358.32, down from CNY 30,122,367.24, a decrease of approximately 8.84%[15] - Other comprehensive income after tax for Q3 2024 was CNY 7,490,193.67, compared to CNY 11,276,904.90 in Q3 2023, a decrease of about 33.5%[16] - Investment income for Q3 2024 was CNY 4,740,181.17, significantly lower than CNY 44,103,057.30 in Q3 2023, a decline of approximately 89.29%[16] Current Assets and Inventory - Cash and cash equivalents increased by ¥80,574,439.82, a growth of 115.43% year-over-year, driven by higher operating cash flow[8] - The company's cash and cash equivalents increased to ¥61,896,678.44 from ¥51,127,203.84, representing a growth of approximately 21.5%[11] - Total current assets rose to ¥1,040,122,716.05 from ¥896,074,387.79, indicating an increase of about 16.1%[12] - The company's accounts receivable increased to ¥295,069,893.70 from ¥259,180,458.29, which is an increase of about 13.8%[11] - Inventory decreased to ¥221,548,287.80 from ¥231,123,272.84, showing a decline of approximately 4.1%[12] - The total non-current assets decreased slightly to ¥1,412,562,393.55 from ¥1,440,414,236.14, a decrease of about 1.9%[12] - The company's short-term borrowings decreased to ¥79,795,291.53 from ¥95,120,023.87, a reduction of approximately 16.1%[12]